½ÃÀ庸°í¼­
»óǰÄÚµå
1392090

¼¼°è º¹ÇÕ È­ÇÐ ¿ä¹ý ½ÃÀå : ¾àÁ¦ À¯Çüº°, ¹èÇÕ È¯°æº°, Åõ¿© °æ·Îº°, ȯÀÚ À¯Çüº°, ¾Ï À¯Çüº°, À¯Åë ä³Îº°, ¹èÇÕ ¹æ¹ýº°, Æ÷Àå À¯Çüº°, ±ÔÁ¦ ´ëÀÀº°, Áö¿ªº°

Compounding Chemotherapy Market, By Drug Type, By Compounding Setting, By Route of Administration, By Patient Type, By Cancer Type, By Distribution Channel, By Compounding Method, By Packaging Type, By Regulatory Compliance, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è º¹ÇÕ È­ÇÐ ¿ä¹ý ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 52¾ï 9,000¸¸ ´Þ·¯·Î Æò°¡·Î Æò°¡µÇ¾ú°í 2023³âºÎÅÍ 2030³â¿¡ °ÉÃÄ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 4.9%¸¦ ³ªÅ¸³¾ Àü¸ÁÀ̸ç 2030³â¿¡´Â 74¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁسâ 2022³â 2023³â ½ÃÀå ±Ô¸ð 52¾ï 9,000¸¸ ´Þ·¯
¾÷Àû µ¥ÀÌÅÍ 2018-2021³â ¿¹Ãø ±â°£ 2023³â-2030³â
¿¹Ãø ±â°£ÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 4.90% 2030³â ½ÃÀå ±Ô¸ð ¿¹Ãø 74¾ï 1,000¸¸ ´Þ·¯
±×¸² 1. ¼¼°è º¹ÇÕ È­ÇÐ ¿ä¹ý ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2023³â
Compounding Chemotherapy Market-IMG1

Á¦Çü È­Çпä¹ýÀ̶õ ÀǾàǰ ¼ººÐÀ» °³º° ȯÀÚÀÇ Çʿ信 ¸Â°Ô ¾à¹°·Î ¸ÂÃãÈ­ÇÏ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. ÀÌ ¹è°æ¿¡´Â ¼¼°è ¾Ï ÀÌȯÀ²ÀÇ »ó½Â°ú Ư¼öÇÑ ¾àÁ¦Á¦Á¦ÀÇ Çʿ伺ÀÌ Å©°Ô ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¾Ï Ä¡·á°¡ ´õ¿í °³º°È­µÊ¿¡ µû¶ó È­ÇÕ¹°Àº ȯÀÚ¿¡°Ô ƯÁ¤ Áúº´, »óÅÂ, °¨¼ö¼º¿¡ ÀûÇÕÇÑ Á¦ÇüÀ» Á¦°øÇϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¾ÏÀ» ¹ßº´Çϱ⠽¬¿î ³ëÀÎ Àα¸ Áõ°¡, Á¤¹ÐÀÇ·á ¹× Ç¥Àû ¿ä¹ý¿¡ ´ëÇÑ ÁßÁ¡È­ Áõ°¡, ½ÃÆÇ ¾àÀÇ ºÎÁ·Àº º¹ÇÕ È­ÇÐ ¿ä¹ý ¼­ºñ½ºÀÇ ¼¼°è º¸±ÞÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÇ ÀϺÎÀÔ´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¾Ï, °ñ¼öÁúȯ, ¸é¿ª°è ¹®Á¦ µî Áúº´ÀÇ À¯º´·ü Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È¿¡µµ ¼¼°è º¹ÇÕ È­ÇÐ ¿ä¹ý ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ó¹æ¾à¿¡ µå´Â ºñ¿ë Áõ°¡¿Í ÁöºÒ Á¤Ã¥ÀÇ º¯È­´Â ¿¹Ãø ±â°£¿¡ °ÉÃÄ ¼¼°è Á¦Çü È­Çпä¹ý ½ÃÀåÀÇ ¼ºÀåÀ» ´Ù½Ã Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¦Ç°¿¡ ÀÇÇÑ ¼ÒºñÀÚÀÇ °Ç°­ ÀÌÁ¡ Áõ°¡´Â ¼¼°è º¹ÇÕ È­ÇÐ ¿ä¹ý ½ÃÀå¿¡ »õ·Î¿î ±âȸ¸¦ âÃâÇÕ´Ï´Ù. º´¿ø°ú ÀÇ·á¾÷°è¿¡¼­´Â ¹èÇÕÈ­Çпä¹ý¿¡ ÀÇÇÑ Ä¡·á³ª ÀǾàǰ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖÀ¸¸ç, À̰͵µ ½ÃÀå È®´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é ¾Ï ÀÌȯ ȯÀÚ ¼ö´Â 2000³â ÀÌÈÄ °ÅÀÇ µÎ¹è°¡ µÇ°í ÀÖÀ¸¸ç, ÇâÈÄ 20³â°£ 70% ÀÌ»ó Áõ°¡°¡ ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ¸ÂÃã Ä¡·áÀÇ ¼±Åðú °¡Ä¡¿¡ ±âÃÊÇÑ ÀÇ·á ¸ðµ¨¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡´Â Á¾¾ç°úÀÇ °³¾÷ÀÇ¿¡°Ô Á¶Á¦ ¼­ºñ½ºÀÇ µµÀÔÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶Ç, ƯÈ÷ ¼Ò¾Æ¾Ï¿¡ ´ëÇÑ ½ÃÆÇ¾àÀÇ ºÎÁ·Àº ÀÌ ½ÃÀåÀÇ ÁøÃâ±â¾÷¿¡ ¼ºÀå ±âȸ¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ±×·¯³ª ¿À¿°ÀÇ À§Çè, º¹ÀâÇÑ Á¦ÇüÀÇ Á¦Á¶¿¡ À־ÀÇ ±â¼úÀû °úÁ¦, ±¹°¡¿¡ ÀÇÇØ Àϰü¼ºÀÌ ¾ø´Â ±ÔÁ¦ ȯ°æÀÌ ½ÃÀå È®´ë¸¦ ¹æÇØÇÒ ¼öµµ ÀÖ½À´Ï´Ù. ¾à±¹¿¡¼­ÀÇ Á¶Á¦¿¡ À־ÀÇ 3D ÇÁ¸°ÆÃÀÇ ÀÀ¿ëÀÌ È®´ëµÇ°í Àֱ⠶§¹®¿¡ ÇâÈÄ ¼ö³â°£¿¡ µå·¯±× µô¸®¹ö¸®ÀÇ °³¼±À̳ª °³º°È­µÈ Åõ¿© ¼³°è°¡ °¡´ÉÇÏ°Ô µÇ¾î, »õ·Î¿î ±æÀÌ ¿­¸± °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • º» º¸°í¼­´Â ¼¼°è º¹ÇÕ È­ÇÐ ¿ä¹ý ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2022³âÀ» ±âÁسâÀ¸·Î ÇÑ ¿¹Ãø±â°£(2023³â-2030³â) ½ÃÀå ±Ô¸ð¿Í º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)À» Á¦°øÇÕ´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾ÈÀÇ Çà·ÄÀ» ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ »ó½Ã¿Í ½ÂÀÎ, ½ÃÀ嵿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀïÀü·« µî¿¡ °üÇÑ Áß¿äÇÑ °íÂûµµ Á¦°øÇÕ´Ï´Ù.
  • ¿£ÅÍÇÁ¶óÀÌÁî ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ½ÇÀû, Àü·« µî°ú °°Àº ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è Á¦Çü È­Çпä¹ý ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®À» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, ŸÀÌÇÎ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°è º¹ÇÕ È­ÇÐ ¿ä¹ý ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è º¹ÇÕ È­ÇÐ ¿ä¹ý ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤ÀÌ ¿ëÀÌÇØÁý´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦

  • Á¶»ç ¸ñÀû
  • °¡Á¤
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
  • ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
  • ¾Ï µîÀÇ Áúº´ÀÇ ÀÌȯÀ² Áõ°¡
    • ¾ïÁ¦¿äÀÎ
  • È­Çпä¹ýÁ¦ÀÇ Á¶Á¦¿¡´Â °í¾×ÀÇ ºñ¿ëÀÌ µç´Ù
    • ±âȸ
  • Á¦Ç°¿¡ ÀÇÇÑ ¼ÒºñÀÚÀÇ °Ç°­»óÀÇ ÀÌÁ¡ Áõ°¡
  • ¿µÇ⠺м®
  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Ç° Ãâ½Ã/½ÂÀÎ
  • PEST ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ÇÕº´°ú Àμö ½Ã³ª¸®¿À

Á¦4Àå º¹ÇÕ È­Çпä¹ý ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿ªÇÐ
  • °ø±ÞÃø°ú ¼ö¿äÃø ºÐ¼®
  • °æÁ¦Àû ¿µÇâ

Á¦5Àå º¹ÇÕ È­ÇÐ ¿ä¹ý ½ÃÀå : ¾àÁ¦ À¯Çüº°(2018³â-2030³â)

  • ¼Ò°³
  • ¼¼Æ÷µ¶¼º¾à
  • È£¸£¸óÁ¦
  • ¸é¿ªÁ¶ÀýÁ¦
  • Ç¥Àû¿ä¹ý
  • ÁöÁö¿ä¹ý¾à

Á¦6Àå º¹ÇÕ È­ÇÐ ¿ä¹ý ½ÃÀå : ¹èÇÕ È¯°æº°(2018³â-2030³â)

  • ¼Ò°³
  • º´¿ø Á¶ÇÕ
  • Á¶Á¦ ¾à±¹
  • Àü¹® Ŭ¸®´Ð
  • ÀçÅÃÄ¡·á

Á¦7Àå º¹ÇÕ È­ÇÐ ¿ä¹ý ½ÃÀå : Åõ¿© °æ·Îº°(2018³â-2030³â)

  • ¼Ò°³
  • Á¤¸Æ³» Åõ¿©(IV)
  • °æ±¸
  • ÇÇÇÏ(SC)
  • ±ÙÀ°³»(IM)
  • ÁöÁÖ¸·Çϰ­³»(IT)

Á¦8Àå º¹ÇÕ È­ÇÐ ¿ä¹ý ½ÃÀå : ȯÀÚ À¯Çüº°(2018³â-2030³â)

  • ¼Ò°³
  • ¼ºÀΠȯÀÚ
  • ¼Ò¾ÆÈ¯ÀÚ
  • ³ëÀΠȯÀÚ

Á¦9Àå º¹ÇÕÈ­Çпä¹ý ½ÃÀå : ¾Ï À¯Çüº°(2018³â-2030³â)

  • ¼Ò°³
  • À¯¹æ¾Ï
  • Æó¾Ï
  • °áÀåÁ÷Àå¾Ï
  • Àü¸³¼±¾Ï
  • ¹éÇ÷º´
  • ¸²ÇÁÁ¾
  • ±âŸ ƯÁ¤ ¾ÏÀÇ À¯Çü

Á¦10Àå º¹ÇÕ È­ÇÐ ¿ä¹ý ½ÃÀå : À¯Åë ä³Îº°(2018³â-2030³â)

  • ¼Ò°³
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦11Àå º¹ÇÕ È­ÇÐ ¿ä¹ý ½ÃÀå : ¹èÇÕ ¹æ¹ýº°(2018³â-2030³â)

  • ¼Ò°³
  • ¹«±ÕÁ¶ÇÕ
  • ºñ¹«±Õ ¹èÇÕ

Á¦12Àå º¹ÇÕ È­ÇÐ ¿ä¹ý ½ÃÀå : Æ÷Àå À¯Çüº°(2018³â-2030³â)

  • ¼Ò°³
  • ¹ÙÀ̾Ë
  • ¾ÚÇ®
  • ÇÁ¸®Çʵå ÁÖ»ç±â
  • º´

Á¦13Àå º¹ÇÕ È­ÇÐ ¿ä¹ý ½ÃÀå : ±ÔÁ¦ ´ëÀÀº°(2018³â-2030³â)

  • ¼Ò°³
  • USP Chapter 797 ÁذÅ
  • FDAÀÇ ±ÔÁ¦
  • EMA ±ÔÁ¦

Á¦14Àå º¹ÇÕ È­ÇÐ ¿ä¹ý ½ÃÀå : Áö¿ªº°(2018³â-2030³â)

  • ¼Ò°³
  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • À¯·´
  • µ¶ÀÏ
  • ¿µ±¹
  • ÇÁ¶û½º
  • ÀÌÅ»¸®¾Æ
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • È£ÁÖ
  • Çѱ¹
  • ASEAN ±¹°¡
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿
  • GCC ±¹°¡
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«

Á¦15Àå °æÀï ±¸µµ

  • Braun Melsungen AG
  • Fagron NV
  • PharMEDium Services, LLC(AmerisourceBergen Corporation)
  • Baxter International Inc.
  • Fresenius Kabi AG
  • Advanced Pharma, Inc.
  • McGuff Compounding Pharmacy Services, Inc.
  • Central Admixture Pharmacy Services, Inc.(CAPS)
  • Institutional Pharmacy Solutions, LLC
  • Wedgewood Pharmacy
  • Medisca Inc.
  • Doughertys Holdings, Inc.
  • PharMEDium Services, LLC(AmerisourceBergen Corporation)
  • BioScrip, Inc.

Á¦16Àå ¼½¼Ç

  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç¿¡ ´ëÇØ
BJH 23.12.21

The Global Compounding Chemotherapy Market size was valued at US$ 5.29 Bn in 2023 and is projected to reach US$ 7.41 Bn by 2030, growing at a CAGR of 4.9% from 2023 to 2030.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 5.29 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 4.90% 2030 Value Projection: US$ 7.41 Bn
Figure 1. Global Compounding Chemotherapy Market Share (%), by Region, 2023
Compounding Chemotherapy Market - IMG1

Compounding chemotherapies refer to the customization of pharmaceutical ingredients into medication tailored to individual patient needs. This has been largely driven by the rise in cancer prevalence worldwide and the need for specialized drug formulations. As cancer treatments become more personalized, compounding plays a crucial role in providing patients with formulations suited to their specific disease, condition, or sensitivity. Growing geriatric population prone to developing cancers, increasing emphasis on precision medicine and targeted therapies, and shortages of commercially available drugs are some of the key factors fueling the adoption of compounding chemotherapy services globally.

Market Dynamics:

The increasing prevalence of illnesses like cancer, bone marrow conditions, and immune system problems will continue to fuel the growth of the global compounding chemotherapy market over the forecast period. Increasing costs for prescription drugs and changing payment policies are again expected to augment global compounding chemotherapy market growth over the forecast period. Rising consumer health benefits from the products will create new opportunities for the global compounding chemotherapy market. Hospitals and the healthcare industry are becoming more aware of compounded chemotherapy treatments or medicines, which is also assisting in the market's expansion.

According to the World Health Organization, the cancer burden has nearly doubled since 2000 and is expected to grow by over 70% in the next two decades. Increased awareness about personalized treatment options and value-based healthcare models is encouraging oncology practitioners to adopt compounding services. The shortage of commercially manufactured drugs, especially for pediatric cancer, also presents growth opportunities for players in this market. However, risks of contamination, technical challenges in preparing complex formulations, and an inconsistent regulatory environment across countries could hinder the market expansion to some extent. The growing application of 3D printing in pharmacy compounding is likely to open up new avenues, allowing for improved drug delivery and personalized dosage designs in the coming years.

Key features of the study:

  • This report provides in-depth analysis of the global compounding chemotherapy market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global compounding chemotherapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include B. Braun Melsungen AG, Fagron NV, PharMEDium Services, LLC (AmerisourceBergen Corporation), Baxter International Inc., Fresenius Kabi AG, Advanced Pharma, Inc., McGuff Compounding Pharmacy Services, Inc., Central Admixture Pharmacy Services, Inc. (CAPS), Institutional Pharmacy Solutions, LLC, Wedgewood Pharmacy, Medisca Inc., Dougherty's Holdings, Inc., PharMEDium Services, LLC (AmerisourceBergen Corporation), BioScrip, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global compounding chemotherapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global compounding chemotherapy market

Global Compounding Chemotherapy Market Detailed Segmentation:

  • By Drug Type:
    • Cytotoxic Drugs
    • Hormonal Agents
    • Immunomodulatory Agents
    • Targeted Therapies
    • Supportive Care Drugs
  • By Compounding Setting:
    • Hospital Compounding
    • Compounding Pharmacies
    • Specialty Clinics
    • Homecare Settings
  • By Route of Administration:
    • Intravenous (IV)
    • Oral
    • Subcutaneous (SC)
    • Intramuscular (IM)
    • Intrathecal (IT)
  • By Patient Type:
    • Adult Patients
    • Pediatric Patients
    • Geriatric Patients
  • By Cancer Type:
    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Leukemia
    • Lymphoma
    • Other specific cancer types
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Compounding Method:
    • Aseptic Compounding
    • Non-aseptic Compounding
  • By Packaging Type:
    • Vials
    • Ampoules
    • Pre-filled Syringes
    • Bottles
  • By Regulatory Compliance:
    • USP Chapter <797> Compliance
    • FDA Regulations
    • EMA Regulations
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Company Profile:
    • Braun Melsungen AG
    • Fagron NV
    • PharMEDium Services, LLC (AmerisourceBergen Corporation)
    • Baxter International Inc.
    • Fresenius Kabi AG
    • Advanced Pharma, Inc.
    • McGuff Compounding Pharmacy Services, Inc.
    • Central Admixture Pharmacy Services, Inc. (CAPS)
    • Institutional Pharmacy Solutions, LLC
    • Wedgewood Pharmacy
    • Medisca Inc.
    • Dougherty's Holdings, Inc.
    • BioScrip, Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Compounding Chemotherapy, By Drug Type
    • Market Compounding Chemotherapy, By Compounding Setting
    • Market Compounding Chemotherapy, By Route of Administration
    • Market Compounding Chemotherapy, By Patient Type
    • Market Compounding Chemotherapy, By Cancer Type
    • Market Compounding Chemotherapy, By Distribution Channel
    • Market Compounding Chemotherapy, By Compounding Method
    • Market Compounding Chemotherapy, By Packaging Type
    • Market Compounding Chemotherapy, By Regulatory Compliance
    • Market Compounding Chemotherapy, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Increasing demand for Personalized Medicine
  • Increasing prevalence of illnesses like cancer
    • Restraints
  • The High cost of compounding chemotherapeutic products
    • Opportunities
  • Rising consumer health benefits from the products
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Compounding Chemotherapy Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Compounding Chemotherapy Market , By Drug Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Cytotoxic Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Hormonal Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Immunomodulatory Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Targeted Therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Supportive Care Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Compounding Chemotherapy Market , By Compounding Setting, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • Hospital Compounding
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Compounding Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Homecare Settings
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

7. Compounding Chemotherapy Market , By Route of Administration, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • Intravenous (IV)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Subcutaneous (SC)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Intramuscular (IM)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Intrathecal (IT)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Compounding Chemotherapy Market , By Patient Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • Adult Patients
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Pediatric Patients
  • Geriatric Patients

9. Compounding Chemotherapy Market , By Cancer Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Leukemia
  • Lymphoma
  • Other specific cancer types

10. Compounding Chemotherapy Market , By Distribution Channel, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Online Pharmacies

11. Compounding Chemotherapy Market , By Compounding Method, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • Aseptic Compounding
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Non-aseptic Compounding

12. Compounding Chemotherapy Market , By Packaging Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • Vials
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Ampoules
  • Pre-filled Syringes
  • Bottles

13. Compounding Chemotherapy Market , By Regulatory Compliance, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • USP Chapter <797> Compliance
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • FDA Regulations
  • EMA Regulations

14. Compounding Chemotherapy Market , By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Country, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Country 2019-2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Compounding Setting, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Compounding Method, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Regulatory Compliance, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

15. Competitive Landscape

  • Braun Melsungen AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Fagron NV
  • PharMEDium Services, LLC (AmerisourceBergen Corporation)
  • Baxter International Inc.
  • Fresenius Kabi AG
  • Advanced Pharma, Inc.
  • McGuff Compounding Pharmacy Services, Inc.
  • Central Admixture Pharmacy Services, Inc. (CAPS)
  • Institutional Pharmacy Solutions, LLC
  • Wedgewood Pharmacy
  • Medisca Inc.
  • Dougherty's Holdings, Inc.
  • PharMEDium Services, LLC (AmerisourceBergen Corporation)
  • BioScrip, Inc.
  • Analyst Views

16. Section

  • Research Methodology
  • About us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦